Pharma & Healthcare
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Research Report 2026
- Mar 17, 26
- ID: 741406
- Pages: 104
- Figures: 91
- Views: 2
This report delivers a comprehensive overview of the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Monoclonal Antibody Anti-VEGF Ophthalmic Drugs. The Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Novartis
Coherus BioSciences
Segment by Type
Faricimab
Brolucizumab
Brolucizumab
Other
by Application
Age-related Macular Degeneration
Diabetic Retinopathy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Novartis
Coherus BioSciences
Segment by Type
Faricimab
Brolucizumab
Brolucizumab
Other
by Application
Age-related Macular Degeneration
Diabetic Retinopathy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Overview
1.1 Product Definition
1.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type
1.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type: 2025 vs 2032
1.2.2 Faricimab
1.2.3 Brolucizumab
1.2.4 Brolucizumab
1.2.5 Other
1.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application
1.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application: 2025 vs 2032
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Retinopathy
1.3.4 Other
1.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021–2032
1.4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021–2032
1.4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competition by Manufacturers
2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
2.8 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Scenario by Region
3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2032
3.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2026
3.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2027–2032
3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2032
3.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2026
3.3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2027–2032
3.4 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.4.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.5.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.7.3 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2032)
4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2026)
4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027–2032)
4.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2032)
4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2032)
4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2026)
4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027–2032)
4.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2032)
5.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2026)
5.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027–2032)
5.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2032)
5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2032)
5.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2026)
5.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027–2032)
5.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Chain Analysis
7.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Mode & Process Analysis
7.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales and Marketing
7.4.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Channels
7.4.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
7.5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customer Analysis
8 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Dynamics
8.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Trends
8.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
8.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
8.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type
1.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type: 2025 vs 2032
1.2.2 Faricimab
1.2.3 Brolucizumab
1.2.4 Brolucizumab
1.2.5 Other
1.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application
1.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application: 2025 vs 2032
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Retinopathy
1.3.4 Other
1.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021–2032
1.4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021–2032
1.4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competition by Manufacturers
2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
2.8 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Scenario by Region
3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2032
3.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2026
3.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2027–2032
3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2032
3.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2026
3.3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2027–2032
3.4 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.4.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.5.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.7.3 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2032)
4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2026)
4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027–2032)
4.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2032)
4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2032)
4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2026)
4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027–2032)
4.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2032)
5.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2026)
5.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027–2032)
5.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2032)
5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2032)
5.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2026)
5.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027–2032)
5.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Chain Analysis
7.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Mode & Process Analysis
7.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales and Marketing
7.4.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Channels
7.4.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
7.5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customer Analysis
8 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Dynamics
8.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Trends
8.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
8.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
8.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List
Table 88. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers List
Table 89. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Trends
Table 90. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
Table 91. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
Table 92. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Faricimab Product Picture
Figure 5. Brolucizumab Product Picture
Figure 6. Brolucizumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 10. Age-related Macular Degeneration
Figure 11. Diabetic Retinopathy
Figure 12. Other
Figure 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), 2021–2032
Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 18. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in 2025
Figure 21. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List
Table 88. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers List
Table 89. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Trends
Table 90. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
Table 91. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
Table 92. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Faricimab Product Picture
Figure 5. Brolucizumab Product Picture
Figure 6. Brolucizumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 10. Age-related Macular Degeneration
Figure 11. Diabetic Retinopathy
Figure 12. Other
Figure 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), 2021–2032
Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 18. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in 2025
Figure 21. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232